A practical reference on research compound: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-27 and is reviewed periodically as new material appears.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Here J denotes current density(whose direction is against electron flow by convention) due to electron flow within the considered volume of the semiconductor. It is also called electron current density. Total electron current density is the sum of drift current and diffusion current densities:
The ancestors of modern reptiles (which belong to the clade Sauria) had diverged from each other by the Late Permian, as evidenced by species such as the monitor lizard-like Protorosaurus known from the Late Permian of Europe, which is clearly an archosauromorph, more closely related to archosaurs (crocodilians and birds) than to lizards, snakes or turtles.
Analysis of clinical trial results that includes all data from participants in the groups to which they were randomized even if they never received the treatment. (NLM) The principle that asserts that the effect of a treatment policy can be best assessed by evaluating on the basis of the intention to treat a subject (i.e. the planned treatment regimen) rather than the actual treatment given. It has the consequence that subjects allocated to a treatment group should be followed up, assessed and analysed as members of that group irrespective of their compliance to the planned course of treatment. (ICH E9) Interaction (Qualitative & Quantitative)
In 2020, world production of soybeans was over 353 million tonnes, led by Brazil and the United States combined with 66% of the total (table). Production has dramatically increased across the globe since the 1960s, but particularly in South America after a cultivar that grew well in low latitudes was developed in the 1980s. The rapid growth of the industry has been primarily fueled by large increases in worldwide demand for meat products, particularly in developing countries like China, which alone accounts for more than 60% of imports. Soy is a staple crop; global soy production accounts for four times more legume production than all other legumes combined.
Sources: en.wikipedia.org
For services to Higher Education. Carol Stump. Lately, President, Libraries Connected. For services to Public Libraries. Jacqueline Penelope Suttie. Founder and Chief Executive Officer, PTSD UK. For services to People with Post Traumatic Stress Disorder. Christopher Bennet Symonds. Senior Doorkeeper, House of Commons. For services to Parliament. Bolanle Tajudeen. Founder and Director, Bolanle Contemporary and Founder and Director, Black Blossoms. For services to the Arts. Deborah Janine Tann. Chief Executive, Hampshire and Isle of Wight Wildlife Trust. For services to Wildlife and the Natural Environment. Dr. Muhammad Saleem Khan Tareen. Psychiatrist, Northern Health and Social Care Trust. For services to Mental Ill Health and to Community Development in Northern Ireland. Jenny Thompson. Co-Founder and Director, Market Operations. For services to the Business and Food Sectors. Laurence Joseph Thraves. Head, National Situation Centre, Cabinet Office. For Public Service. Troy Donoghue Townsend. Head of Player Engagement, Kick It Out. For services to Diversity and Inclusion in Association Football. Deborah Ann Turnbull. Founder and Director, River and Sea Sense. For services to Water Safety Education for Young People and Families. Steven Underwood. Lately Mathematics Teacher, Ryedale School, Beadlam, North Yorkshire. For services to Education. Robin Arden Varley. Chair, Cricket Wales North Area Board, Cricket Wales Ltd. For services to Cricket in Wales. Sarah Vaughan. Deputy Head Teacher, Perryfields Primary Pupil Referral Unit, Worcester. For services to Education.
=== Macroscopic examination === Visual examination of the specimen may provide information to the pathologist or the physician. For example, fluid drained from an abscess may appear cloudy, or cerebrospinal fluid obtained by lumbar puncture may exhibit xanthochromia, suggesting a bleed has occurred. Laboratory technologists may provide qualitative descriptions accordingly.
== Prizes and awards == 2023: VinFuture, Innovators with Outstanding Achievements in Emerging Fields – Jens Juul Holst, Joel Francis Habener, Daniel Joshua Drucker and Svetlana Mojsov 2023: Nature 10 most influential people who shaped science 2024: Pearl Meister Greengard Prize by the Rockefeller University 2024: Time 100 Most Influential People, Pioneers section 2024: Princess of Asturias Awards, Technical and Scientific Research – Daniel J. Drucker, Jeffrey M. Friedman, Joel F. Habener, Jens Juul Holst and Svetlana Mojsov 2024: Tang Prize, Biopharmaceutical Science – Joel F. Habener, Svetlana Mojsov and Jens Juul Holst 2024: Lasker-DeBakey Clinical Medical Research Award – Joel Habener, Svetlana Mojsov and Lotte Bjerre Knudsen 2024: BBVA Foundation Frontiers of Knowledge Awards - Biology and Biomedicine - Daniel Joshua Drucker, Joel Habener, Jens Juul Holst and Svetlana Mojsov 2025: Breakthrough Prize in Life Sciences - Daniel J. Drucker, Joel Habener, Jens Juul Holst, Lotte Bjerre Knudsen and Svetlana Mojsov; Alberto Ascherio and Stephen L. Hauser; and David R. Liu 2025: Warren Triennial Prize – Joel Habener, Daniel J.
Holtz and Zanno both remarked that it was plausible that more than one species of Tyrannosaurus existed, but felt the new study was insufficient to support the species it proposed. Holtz remarked that, even if Tyrannosaurus imperator represented a distinct species from Tyrannosaurus rex, it may represent the same species as Nanotyrannus lancensis and would need to be called Tyrannosaurus lancensis. O'Connor, a curator at the Field Museum, where the T. imperator holotype Sue is displayed, regarded the new species as too poorly-supported to justify modifying the exhibit signs. Brusatte, Carr, and O'Connor viewed the distinguishing features proposed between the species as reflecting natural variation within a species. Both Carr and O'Connor expressed concerns about the study's inability to determine which of the proposed species several well-preserved specimens belonged to. Another paleontologist, Philip J. Currie, originally co-authored the study but withdrew from it as he did not want to be involved in naming the new species. In a subsequent paper published in 2025, Paul maintained the validity of T. imperator and T. regina, arguing that these proposed species could be further distinguished by the shape of their postorbital bosses (bony rugosities behind the eyes).
Regarding physical trauma or disease suffered by an organism, healing involves the repairing of damaged tissue(s), organs and the biological system as a whole and resumption of (normal) functioning. Medicine includes the process by which the cells in the body regenerate and repair to reduce the size of a damaged or necrotic area and replace it with new living tissue. The replacement can happen in two ways: by regeneration in which the necrotic cells are replaced by new cells that form "like" tissue as was originally there; or by repair in which injured tissue is replaced with scar tissue. Most organs will heal using a mixture of both mechanisms. Within surgery, healing is more often referred to as recovery, and postoperative recovery has historically been viewed simply as restitution of function and readiness for discharge. More recently, it has been described as an energy‐requiring process to decrease physical symptoms, reach a level of emotional well‐being, regain functions, and re‐establish activities. Healing is also referred to in the context of the grieving process. In psychiatry and psychology, healing is the process by which neuroses and psychoses are resolved to the degree that the client is able to lead a normal or fulfilling existence without being overwhelmed by psychopathological phenomena. This process may involve psychotherapy, pharmaceutical treatment or alternative approaches such as traditional spiritual healing.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.